<DOC>
	<DOCNO>NCT01535222</DOCNO>
	<brief_summary>The purpose study demonstrate periprocedural infusion escalate dos MDCO-2010 safe tolerate patient undergo elective CABG surgery , characterize single dose pharmacokinetics MDCO-2010 , investigate effect MDCO-2010 pharmacodynamics ( biomarkers fibrinolysis coagulation parameter ) , investigate effect exploratory clinical endpoint bleed , transfusion requirement reexploration .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics MDCO-2010 Patients Undergoing Elective Coronary Artery Bypass Graft Surgery</brief_title>
	<detailed_description>This protocol describe study investigational drug MDCO-2010 haemostasis modulator patient undergo elective Coronary Artery Bypass Graft ( CABG ) surgery involve cardiopulmonary bypass ( CPB ) . Perioperative bleed serious complication adversely affect morbidity mortality cardiac surgery . To alleviate complication , prophylactic antifibrinolytic therapy widely accept strategy inhibit excessive fibrinolysis . MDCO-2010 , synthetic small molecule , direct inhibitor plasmin plasma kallikrein . Both implicated impaired haemostasis . In addition , potent inhibition coagulation factor Xa , XIa activate Protein C demonstrate . Thus , MDCO-2010 potential mitigate excessive fibrinolysis thrombin generation cardiac surgery involve cardiopulmonary bypass . In particular latter suppose provide additional benefit beyond reduce transfusion requirement .</detailed_description>
	<criteria>Inclusion Criteria Men , age 18 80 year Postmenopausal woman , age 80 year . Postmenopausal status define ≥ 1 year since last menstruation woman medical history hysterectomy woman medical history bilateral oophorectomy Planned elective , isolated primary CABG surgery 1 graft , include use cardiopulmonary bypass Written inform consent prior studyrelated procedure part normal medical care Exclusion Criteria Patients may meet follow exclusion criterion : Planned concomitant surgery include atrial septal defect ( ASD ) repair , valve replacement , carotid endarterectomy , aortic surgery , combine procedure repeat sternotomy Planned Offpump CABG Body weight &lt; 55 kg &gt; 110 kg Planned hypothermia &lt; 28°C Major surgical procedure within 30 day entry Placement drugeluting stent ( DES ) within 12 month baremetal stent ( BMS ) within 6 week entry vessel intend graft Ejection fraction &lt; 35 % Preoperative coagulation abnormality Platelet count &lt; 100,000/cubic mm , INR &gt; 1.5 Quick &lt; 40 % , activate partial thromboplastin time ( aPTT ) &gt; 1.5 x upper limit normal ( ULN ) Preoperative Hb &lt; 11 g/dL male patient &lt; 10 g/dL female patient Patient refusal receive donor blood product necessary Administration thienopyridines within 5 day prior surgery Administration warfarin within 5 day prior surgery Administration tirofiban eptifibatide within 24 hour administration abciximab within 5 day prior surgery Administration fondaparinux within 24 hour prior surgery Creatinine clearance ( calculate use CockroftGault equation ) &lt; 60 mL/min Planned intraoperative use tranexamic acid εaminocaproic acid History stroke transient ischemic attack within 3 month prior entry Known heparininduced thrombocytopenia Known history thrombophilia , eg , deep vein thrombosis ( DVT ) pulmonary embolism Active liver disease Any condition require chronic immunosuppressive medication Receipt investigational drug device 30 day prior entry Any condition , opinion investigator , would prevent patient 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>cardiac surgery</keyword>
	<keyword>coronary artery bypass graft</keyword>
	<keyword>cardiopulmonary bypass</keyword>
	<keyword>haemostasis modulator</keyword>
	<keyword>blood loss</keyword>
	<keyword>direct inhibitor plasmin plasma kallikrein</keyword>
	<keyword>CABG</keyword>
	<keyword>CPB</keyword>
</DOC>